Columvi (glofitamab)

pCPA File Number: 23328

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0406-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable